Pre-emptive treatment of acute GVHD: A randomized multicenter trial of rabbit anti-thymocyte globulin, given on day7 after alternative donor transplants

A. Bacigalupo, T. Lamparelli, G. Milone, M. P. Sormani, F. Ciceri, J. Peccatori, A. Locasciulli, I. Majolino, P. Di Bartolomeo, F. Mazza, N. Sacchi, S. Pollicheni, V. Pinto

Research output: Contribution to journalArticle

Abstract

We have previously shown that hemopoietic stem cell transplant (HSCT) recipients can be stratified on day + 7 as having low, intermediate or a high risk of transplant-related mortality (TRM). With the aim of reducing TRM and GVHD, intermediate and high-risk patients (n=170) were randomized to receive anti-thymocyte globulin (ATG, thymoglobuline) on day + 7 (n=84) or no treatment (n=86) (controls). There was a reduction of TRM from 35% in controls to 29% in ATG patients (P=0.3), of acute GVHD III-IV from 15 to 5% (P=0.02) and of chronic GVHD from 26 to 11% (P=0.03); survival was comparable. The predictive value of the day + 7 score on TRM was confirmed for controls (19 vs 42% for intermediate vs high risk, respectively, P=0.03), whereas ATG abrogated this predictive effect (29 vs 29%). ATG reduced GVHD (P=0.006) in high-risk patients, but not in patients with an intermediate risk. In conclusion, we confirm that TRM can be predicted on the basis of day + 7 laboratory values, after alternative donor HSCT; in high-, but not intermediate-risk patients, the administration of ATG on day + 7 reduces GVHD. These results may represent a platform for risk-adapted post transplant immune modulation.

Original languageEnglish
Pages (from-to)385-391
Number of pages7
JournalBone Marrow Transplantation
Volume45
Issue number2
DOIs
Publication statusPublished - Feb 2010

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Bacigalupo, A., Lamparelli, T., Milone, G., Sormani, M. P., Ciceri, F., Peccatori, J., Locasciulli, A., Majolino, I., Di Bartolomeo, P., Mazza, F., Sacchi, N., Pollicheni, S., & Pinto, V. (2010). Pre-emptive treatment of acute GVHD: A randomized multicenter trial of rabbit anti-thymocyte globulin, given on day7 after alternative donor transplants. Bone Marrow Transplantation, 45(2), 385-391. https://doi.org/10.1038/bmt.2009.151